In spite of tremendous improvements made over the past decade for the treatment of ophthalmology diseases and conditions, there remains a dramatic unmet medical need for treatments that can stop apoptosis of important retinal cells, including photoreceptors. We believe that developing new therapies in this ophthalmology area is positioned as the next frontier in ophthalmology drug development. Both dry and wet forms of AMD conditions may lead to vision loss due to the lack of treatments that are capable of preventing the death of the main retinal cells. Therefore, there is a huge market for a treatment that is capable of protecting vision by preventing the apoptosis of retinal cells, which is related to various forms of AMD.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Key buying criteria

PART 06: AMD: Overview

Understanding the disease

Stages of AMD

Etiology

Signs and symptoms

Diagnosis

Management

PART 07: Pipeline portfolio

PART 08: Market landscape

Market overview

PART 09: Market analysis of major drugs

Lucentis

Eylea

Avastin

Five forces analysis

PART 10: Market segmentation by type

Global wet AMD market

Market overview

Global dry AMD market

Market overview

PART 11: Market segmentation by ROA

IV

Intravitreal

PART 12: Geographical segmentation

AMD market in Americas

AMD market in EMEA

AMD market in APAC

PART 13: Market drivers

Increase in aging population

Increasing reimbursement benefits for AMD drugs

Increase in diagnosis rate

High patient and physician satisfaction

PART 14: Impact of drivers

PART 15: Market challenges

Gap in patient demand vs. ophthalmology expert

supply

Increasing use of off-label drugs

Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends

Novel treatment approaches for developing AMD

drugs

Increased research grants, initiatives, and programs

Use of combination therapies

PART 18: Vendor landscape

Competitive scenario

Other prominent vendors

PART 19: Key vendor analysis

Bayer HealthCare

F. Hoffmann-La Roche

Novartis

Regeneron Pharmaceuticals

PART 20: Appendix

List of abbreviations

PART 21: Explore Technavio